LETTERS TO T he recent paper by Jang et al. (1) , highlighted in In This Issue (2) , is part of a recent rediscovery of the myeloid compartment of the intestinal lamina propria, which is probably the largest macrophage population in the body. The authors refer to these cells as dendritic cells, based on their expression of surface markers such as CD11c, but a dendritic cell was originally defined as a cell that can present Ag to naive T cells. The large majority of the stellate (or dendritic) cells of the intestinal lamina propria expresses the macrophage-specific F4/80 Ag, which is lost from mature Ag-representing cells, and also expresses the CSF-1 receptor and a CSF-1R-EGFP reporter gene (3) (see images of F4/80 and CSF-1R online ͗www. macrophages.com͘). The majority of the so-called dendritic cells of the lamina propria is clearly phagocytic (1) . Some 15 years ago, the myeloid cells of mouse lamina propria were isolated, and the cells that could actually stimulate naive T cells in a MLR were selectively enriched in the nonphagocytic population (4) . By contrast, the F4/80-positive phagocytes, which were also strongly class II-MHC-positive, caused indomethacinsensitive repression of T cell activation. It is inescapable that the large majority of the cells studied by Jang et al. (1) are not dendritic cells by the functional definition, and there is no evidence that all, or indeed any, of them ever become cells that can present Ag to naive T cells. They are the lamina propria macrophages. They might acquire Ag-presenting activity. On the other hand, they might actually be more important to the maintenance of tolerance. high (R2) cell populations with dendritic morphology were abundantly found and were strongly positive for a DC-specific marker, DEC-205. With regard to F4/80 expression, R1 subset was clearly negative, but R2 was moderately positive. Functional analysis revealed that both R1 and R2 subsets can present alloantigen to naive T cells just as effectively as splenic DC and lymph node DC (Fig. 1B, left column) and can also present OVA efficiently to OVA-TCR expressing T cells (Fig. 1B,  right column) . Thus, these DEC-205 ϩ LP-DC have the hallmark of DC, i.e., potent Ag-presenting abilities to T cells.
Then, are the intestinal F4/80-positive, MHC class II-positive phagocytic macrophages described by Dr. Hume's group (3) also found in our analysis? The answer seems yes. They appear to represent CD11c int CD11b high cell population (R3) because they are strongly F4/80 positive, DEC-205 negative (Fig.  1A) , and also strongly positive for MHC class II expression (data not shown). Although this cell population was hardly detectable in our original analysis (2) , the use of 17.5% Accudenz solution instead of 15.5% solution in the present series of analysis allowed us to visualize such cells.
Collectively, by functional definition, LP-DC (2) are indeed DC with potent Ag-presenting abilities. Dr. Hume's finding (3) is also correct that macrophages are present in substantial numbers in the small intestinal LP, but they appear clearly distinguishable from the LP-DC (2). 
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CD25
ϩ regulatory T cell (Treg), rather than their deletion as has been previously assumed. The majority of the data in the Kohm et al. article comes from the use of the 7D4 (rat IgM) Ab. We believe it is important to emphasize that, overwhelmingly, "Treg depletion" studies use a different clone, PC61 (rat IgG1). Kohm et al. suggest that down-modulation of CD25 after Ab treatment could lead to a misinterpretation that CD25-expressing cells are removed. This may be the case when using 7D4. However, using FACS analysis at the single cell level, we have previously reported that PC61 administration leads to a rapid and dramatic loss of CD25 ϩ
Foxp3
ϩ cells without a corresponding increase in CD25
Ϫ
Foxp3
ϩ cells (2) . These data lead inevitably to the conclusion that the commonly used PC61 Ab does, in fact, deplete CD25-expressing Treg.
So we are left with the interesting situation of two anti-CD25 Abs having very different effects. This is perhaps not surprising given their difference in isotype. These differences seem to be reflected in disease. Kohm et al. have previously reported that 7D4 does not influence the course of experimental autoimmune encephalomyelitis (EAE) after optimal immune priming (3, 4) , whereas their most recent data do show exacerbation when priming is suboptimal (1) . In contrast, we and others have found PC61 treatment to exacerbate/prolong EAE after both optimal and suboptimal priming (2, 5-7). As a whole, these studies indicate that Treg do have a controlling influence over optimal disease, and their removal using PC61 allows for an increase in severity and/or failure to recover. 7D4 appears not to achieve this, but perhaps perturbs the Treg/T-aggressor balance sufficiently to allow the conversion of silent autoimmunity into overt autoaggression in the setting of suboptimal priming. It will be important to dissect the mechanisms underlying disease modification in both these settings. (1). Using FACS analysis in both cases, we enumerated CD4 ϩ CD25 ϩ and CD4 ϩ FOXP3 ϩ cells in blood, spleen, and lymph nodes isolated from mice treated with either 7D4 or PC61 (Fig. 1) . Similarly to Kohm et al., we found that despite the disappearance of surface CD25 expression, FOXP3 ϩ cell frequency is not affected by 7D4 administration, irrespective of the tissue analyzed and independently of the dose used (up to 3 mg/mouse). In contrast, injection of as little as 500 g/mouse of PC61 resulted in both the disappearance of CD25 ϩ cells and the loss of CD4 ϩ
FOXP3
ϩ cells. In PBL, the frequency of CD4 cells expressing FOXP3 is reduced from an average of 8 to 3%, indicating that Ͼ65% of the total FOXP3 ϩ cells are depleted. The disappearing cells are the bulk of the FOXP3 ϩ CD25 ϩ T R , while the pre-existing FOXP3 ϩ
CD25
Ϫ subset appeared maintained. In spleen, ϳ45% of the FOXP3 ϩ cells were depleted. T R originally CD25
ϩ that lost CD25 expression and pre-existing CD25
Ϫ T R appeared to contribute equally to the remaining FOXP3 ϩ cell pool. In lymph nodes, depletion was less marked and corresponded to the disappearance of 33% of the FOXP3 ϩ CD25 ϩ . Increasing the amount of PC61 injected (up to 3 mg/mouse) did not dramatically increase the depletion efficiency (data not shown). We conclude that injection of the rat-IgG PC61 mAb, which has been the most frequently used to interfere with T R function in vivo, does result in depletion of a large fraction of T R . 
؉ T Regulatory Cells" I t is indeed important to dissect the mechanisms by which injection of anti-CD25 mAb may influence both CD4 ϩ CD25 ϩ regulatory T cell (T R ) function and responder T cell functionality in vivo. This important need was the motivation of the current studies. While our current study does focus on the use of the 7D4 clone, we have observed similar findings using the PC61 clone (see Fig. 3 of Ref. 1). However, differences do exist.
Basic immunology tells us that an Ab of the isotype of IgM should be more efficient in fixing complement, and hence, serve to more efficiently deplete a target cell population. Interestingly, a previous study reported that neither PC61 nor 7D4 "induced a strong complement-mediated cytotoxicity" (2) . We have tested this ourselves and have found that 7D4, but not PC61, fixes complement in vitro. Thus, we are left with the question that if PC61 indeed cannot fix complement, then by what mechanism does it deplete CD4 ϩ CD25 ϩ T R ? Based on the capacity of fixing complement, it would seem that if either Ab were to be successful in depleting a target cell population, it would be the clone capable of fixing complement, i.e., 7D4. In vitro, as determined by triple staining of target T cells to measure the expression of CD4, CD25, and intracellular Foxp3, we have observed that CD25 expression is quickly down-regulated following exposure to either 7D4 or PC61 in the absence of cell depletion. In vivo, a fundamental difference between these two clones appears as revealed by the kinetics of CD25 expression, which is quickly down-regulated following in vivo treatment with 7D4. In comparison, the kinetics of PC61-induced CD25 Figure 1 . C57BL/6 mice (8 wk old) raised in specific pathogen-free conditions were injected i.p. once with anti-CD25 mAb clone 7D4 (3 mg) or PC61 (500 g). Splenocytes, lymph node cells, and PBL were isolated 3 days after from either control or treated mice and analyzed by flow cytometry for CD4, FOXP3, and CD25 expression (for CD25 visualization, clone 7D4 or PC61 was used when PC61 or 7D4 was injected, respectively). A, Representative staining of splenocytes (gated on CD4 ϩ cells) analyzed for CD25 and FOXP3 expression. Number inside dot plots represents average Ϯ SD of the percentage of FOXP3 ϩ among CD4
ϩ FOXP3 ϩ in PC61-injected mice vs control or 7D4-injected mice. Data represent the average Ϯ SD for each group (n ϭ 3). One of three independent experiments is shown.
down-regulation are slightly delayed; however, the effects appear to be longer-lasting than that of 7D4. Regardless of which isotype is used, we often see that CD25 expression returns to control levels within 7-10 days of the last treatment. It was this finding that originally prompted us to investigate the alternative actions of anti-CD25 mAb treatment, as it was hard to envision how the CD4 ϩ CD25 ϩ T R population could return to control levels within that time frame if the cells were physically depleted.
We are still investigating whether injection of PC61 results in a partial depletion of CD4 ϩ
ϩ T R and the potential contribution that partial depletion may make to the differences in CD25 expression kinetics between the two Ab clones. While we cannot comment on the purported depletion of CD4 ϩ CD25 ϩ T R referenced by our colleagues (3), because Stephens and Anderton used a single dose of anti-CD25 mAb at a concentration double than we used in our studies, this difference is an obvious source for potential differences in the outcome of anti-CD25 mAb treatment. Furthermore, Zelenay and Demengeot (4) only observed partial deletion of CD4 ϩ CD25 ϩ T R using PC61. Our studies have revealed that decreasing the dose of anti-CD25 mAb treatment does decrease the duration of CD25 down-regulation.
In regards to the findings of McGeachy et al. (5) concerning the effects of PC61 on experimental autoimmune encephalomyelitis progression in disease induced under "optimal" priming conditions, it would be inappropriate for us to compare our findings to their report in light of the fact that the two model systems use distinct strains of mice, priming Ags, and priming protocols and that significant strain differences exist in regards to the functionality of CD4 ϩ CD25 ϩ T R . In sum, our data using clone 7D4 clearly demonstrate that CD25 down-regulation, in the absence of overt CD25 T R depletion (as confirmed by Zelenay and Demengeot, Ref. E verhart et al. (1) reported that endotoxin-induced lung edema was completely prevented by NF-B inhibition and incompletely by neutrophil depletion. Factors other than pulmonary neutrophilia were also involved in the pathogenesis of endotoxin-induced pulmonary edema, which the authors stated are currently not well defined. Some of these factors are well defined and are the cytokines TNF, IL-1, and IFN-␥ and their mediator NO. These cytokines contribute to pulmonary edema by a reduction of alveolar sodium and chloride and associated fluid transport (2) . TNF reduced epithelial sodium channel mRNA expression in alveolar epithelial cells (3). IL-1 was noted to reduce cystic fibrosis transmembrane conductance regulator chloride channel function and epithelial sodium channel expression in alveolar type II cells. IFN-␥ reduced cystic fibrosis transmembrane conductance regulator mRNA in respiratory epithelial cells (2) . In meningococcal septicemia, pulmonary edema was associated with reduced epithelial chloride transport (4) .
NO is released by distal lung epithelial cells and alveolar macrophages in response to TNF, IL-1, and IFN-␥ (2) and reduced sodium transport in alveolar epithelial cells (5) . Neutrophil leukocytes are a source of both TNF and IL-1. The lung edema in neutrophil depleted mice was probably induced by these mediators generated by cells other than neutrophils like local macrophages. Future research into the effects of NF-B inhibition on pulmonary edema needs to focus on TNF, IL-1, IFN-␥, and NO production and the associated changes in alveolar ion and fluid transport.
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